Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

946904

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on the implementation of the Cancer Strategy in relation to breast cancer.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	167281
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>NHS England is committed to transforming cancer care across England for all cancers, including breast cancer, aiming to reduce inequality and promoting equity of access to services. To support this ambition, NHS England has committed more than £200 million in 2017/18 and 2018/19 to fund Cancer Alliances to accelerate early diagnosis of cancer, improve survival and enhance quality of life.</p><p> </p><p>In February 2018, in partnership with the Department and NHS England, Public Health England (PHE) launched a Be Clear on Cancer Campaign focused on Breast Cancer in women aged over 70 to raise awareness of specific symptoms and encourage those with symptoms to visit their doctor.</p><p> </p><p>To improve the uptake of screening, NHS England is continuing to invest in initiatives to help ensure equality of access, including through locally targeted interventions. These include text and general practitioner reminders and PHE’s new ‘Breast screening: easy guide’, which helps women decide whether screening is right for them.</p><p> </p><p>NHS England agreed a Commercial Access Agreement with Roche for Kadcyla (trastuzumab emtansine) which brought the confidential purchase price below the National Institute for Health and Care Excellence cost-effectiveness threshold, allowing approval in routine commissioning. This is offering breast cancer patients precious quality time with their families without damaging side effects.</p><p> </p><p>Finally, we are committed to rolling out stratified follow-up pathways for breast cancer patients by 2020, to ensure patients get the right care after treatment, including information and support to spot signs and symptoms of recurrence or secondary cancer. As well as providing a better experience for patients and ensuring they have the information they need, stratified pathways can offer more effective use of resources by freeing up outpatient capacity. They can also ensure that in cases where there is recurrence or secondary cancer, patients are supported to return to care quickly and effectively.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:03:08 answering member 4067 label Biography information for Steve Brine
	tabling member	4243 label Biography information for Dan Jarvis

946797

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cystic Fibrosis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Adjournment debate of 17 July 2018 on Access to Orkambi, Official Report, cols 377-386, what steps he is taking to (a) facilitate and (b) participate as appropriate in a meeting between the chief executives of NHS England and of Vertex to discuss patient access to lumacaftor-ivacaftor and other medicines for cystic fibrosis.
	tabling member constituency	Bury South
	tabling member printed	Mr Ivan Lewis
	uin	167137
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>As was made clear in the Debate on 17 July 2018, Official report, columns 377-386, Ministers are watching this issue very closely. However, it is vital that we go through the right process. It is the responsibility of the National Institute for Health and Care Excellence (NICE) and NHS England, to work together with Vertex to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>It is an important principle that the National Health Service must ensure that healthcare services secure the best value for patients, and that is the approach NHS England is rightly taking. It is disappointing that Vertex has chosen to withdraw from NICE’s technology appraisal of its latest cystic fibrosis medicine, Symkevi, and NICE and NHS England wrote to Vertex on 31 August to signal their continued willingness to meet with Vertex to discuss access to its new cystic fibrosis medicines.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 15:59:13 answering member 4067 label Biography information for Steve Brine
	tabling member	441 label Biography information for Mr Ivan Lewis

946842

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemophilia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will list the tender board members involved in NHS England's national tender for (a) factor VIII and (b) factor IX haemophilia products; whether any of those board members represent (i) the Northern Ireland Executive and (ii) organisations involved in Northern Ireland; and whether that tender board has ever met in Northern Ireland.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	167275
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>We are informed by NHS England that, the membership of the tender award meetings for the most recent NHS England’s national tenders for factor VIII and factor IX, was made up of representatives of the United Kingdom Haemophilia Centre Doctors' Organisation, officials from NHS England, the Department of Health in Scotland, Wales and Northern Ireland (or their associated procurement organisations), the Pharmaceutical Market Support Group and representatives of patient organisations. Not all organisations attend all meetings.</p><p> </p><p>We can confirm that membership of the tender board on behalf of the Northern Ireland Executive and organisations involved in Northern Ireland was via a government official from the Department of Health in Northern Ireland procurement team. No meetings have been held in Northern Ireland. However, members have remote access, if required.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:09:46 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

946844

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemophilia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 June 2018 to Question 154637 on Haemophilia: Medical Treatments, what the value is of savings which have been made since 2004-05 for (a) factor VIII and (b) factor IX products; how those savings have been reinvested in haemophilia services; and whether those savings have accrued to the (i) the UK Government and (ii) the Northern Ireland Government.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	167276
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>NHS England only holds information for Factor VIII and Factor IX from 2007/8 (up to and including 2017/18). Spend inclusive of VAT over this period is in excess of £2 billion, with savings in excess of £400 million.</p><p> </p><p>Through its commercial activities on all medicines, NHS England uses tendering to drive improvements in the overall value of the medicines it purchases. This approach ensures that the National Health Service as a whole is able to manage increasing demand within existing resources and make investment in approved, evidence based innovative treatments which demonstrate additional value and benefits in patient outcomes.</p><p> </p><p>These figures relate to England only and we do not hold data on equivalent savings in Northern Ireland.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:10:57 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

946845

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemophilia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people who were previously regularly receiving (a) factor VIII and (b) factor IX extended half life (EHLs) products at any point in 2017-18 have since been taken off them; and if he will take steps to ensure that patients are taken off EHLs only when it is clinically necessary.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	167277
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>NHS England has advised data is currently being collected on patients who have switched to Extended Half Life products and will include whether a patient has switched back to a Standard Half Life product. Where the treatment regimen has changed, this is due to patient preference, clear evidence of a lack of benefit or inability to comply with the reporting requirements on patient reported outcome measures. The exact figures are under analysis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:07:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

946866

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemophilia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 June 2018 to Question 154639 on Haemophilia: Medical Treatments, if he will take steps to carry out such a comparative assessment of the uptake of treatment in (a) Ireland, (b) Canada and (c) the EU.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	167278
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>The Department does not routinely make international comparisons on the uptake of individual medicines, and differences in patient demographics, disease burden and clinical practice mean that useful comparison is not always possible. We currently have not plan to undertake an international comparison of haemophilia medicine uptake.</p><p> </p><p>The level of uptake of individual products in England are measured through NHS Digital’s Innovation Scorecard, however this does not include the routine medications for haemophilia.</p><p> </p><p>The Department does publish an indicator for the overall position in competitiveness indicators which can be found in the published Life Sciences Competitiveness Indicators Report at the following link:</p><p> </p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/706963/life-sciences-competitiveness-indicators-2018.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/706963/life-sciences-competitiveness-indicators-2018.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:08:49 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

946867

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemophilia: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to Trigger 1 of Specialised Commissioning Drugs Briefing: Spring 2018, published by NHS England, what assessment he has made of the effect of the faster adoption of best value medicines requirement on the procurement of Extended Half Life factor VIII products; and what factor VIII blood products will be covered by that CQUIN.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	167279
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life factor VIII products to submit prices to be included in the national pricing framework. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.</p><p> </p><p>The aim of trigger 1 of the Medicines Optimisation Commissioning for Quality and Innovation (CQUIN) is to support faster adoption of prioritised best value medicines and treatment regimens as they become available. The factor VIII blood products included in the CQUIN are those from the CMU factor VIII framework which was awarded in July 2018.</p><p> </p><p>There is regular liaison between the CMU and commissioners in NHS England to ensure that the best value products list included in the CQUIN is as up to date as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:06:21 answering member 4067 label Biography information for Steve Brine
	tabling member	4131 label Biography information for Jim Shannon

946897

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for issuing the guidance on influenza vaccines for front line staff.
	tabling member constituency	Leicester South
	tabling member printed	Jonathan Ashworth
	uin	167287
	answer	answer is ministerial correction date of answer 04/09/2018 answer text <p>NHS Improvement and NHS England wrote to National Health Service trusts and foundation trusts on 7 February 2018 to provide advice on which influenza vaccine NHS providers should order for frontline healthcare workers in the 2018/19 season. This advice was sent to ensure that NHS providers order the most clinically effective vaccine for the coming season. A copy of the letter is attached.</p><p> </p><p>A further flu letter will be issued prior to the flu season reiterating this advice and providing additional information on flu vaccination for frontline healthcare workers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/09/2018 16:05:08 answering member 4067 label Biography information for Steve Brine attachment 1 file name 070218 letter Vaccine ordering for 2018-19 influenza season.pdf title PQ167287 attached letter
	tabling member	4244 label Biography information for Jonathan Ashworth

946901

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Food: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for (a) consumers and (b) producers of the frozen vegetable food scare.
	tabling member constituency	Belfast North
	tabling member printed	Nigel Dodds
	uin	167158
	answer	answer is ministerial correction date of answer 06/09/2018 answer text <p>Consumers who have purchased a product affected by the Listeriosis outbreak should return the product to where they have bought it from for a full refund. All consumers using frozen food should follow the cooking instructions and ensure it is thoroughly cooked before serving.</p><p> </p><p>Producers of frozen food should continue to follow good manufacturing practices, conduct appropriate product testing regimes and ensure all frozen food is labelled with clear cooking instructions. The Food Standards Agency continues to monitor the situation and will take further action if required.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/09/2018 15:58:02 answering member 4067 label Biography information for Steve Brine
	tabling member	1388 label Biography information for Lord Dodds of Duncairn

946924

	registered interest
	date	23/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Obesity
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will develop a national obesity strategy for adults and children.
	tabling member constituency	Wolverhampton South West
	tabling member printed	Eleanor Smith
	uin	167352
	answer	answer is ministerial correction date of answer 10/09/2018 answer text <p>There are no current plans to develop a national obesity strategy for adults and children. Many of the key measures in both chapters of our childhood obesity plan will have an impact on tackling obesity across all age groups. These include the soft drinks industry levy, sugar reduction and wider calorie reformulation programme, restricting promotions and calorie labelling in restaurants which will improve our eating habits and reduce the amount of sugar we consume.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/09/2018 16:47:31 answering member 4067 label Biography information for Steve Brine
	tabling member	4609 label Biography information for Eleanor Smith